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Summary 
P815 is a murine mastocytoma of DBA/2 origin which, although immunogenic, rapidly devel- 
ops as a tumor in immunocompetent syngeneic hosts. In this report, we have studied, by a mo- 
lecular approach, the in vivo ot/[~ T  cell response to P815. Both situations of tumor growth af- 
ter  engraftment  of naive  animals  or  tumor  rejection  by preimmunized  animals  have  been 
analyzed.  The spectrum of T  cell receptor [3  chain  rearrangements in the  tumor-infiltrating 
lymphocytes was found to be highly variable among individual tumor-bearing mice. However, 
two rearrangements, one using V[31 and J[31.2  segments and one using the V[31 and J[32.5  seg- 
ments, with conserved junctional regions, reproducibly emerge in most individuals. These two 
rearrangements thus correspond to "public" (recurrent) T  cell clones, as opposed to "private" 
ones, which emerge in a seemingly stochastic fashion in immunized animals. Importantly, these 
public cells are observed in situations of either growth or rejection of the tumor. Quantifica- 
tion provides a clear increase in public T  cells in secondary responses, but no obvious correla- 
tion between their level and primary tumor rejection. The V[31-J[31.2  rearrangement is borne 
by CTL directed against an antigen derived from P1A, a nonmutated mouse self protein which 
is expressed in P815 but not in normal mouse tissues  except testis. A recurrent, public T  cell re- 
sponse can thus be observed to an antigen derived from a self protein expressed by a tumor. 
C 
D8  and CD4 + T  cells  recognize antigenic peptides 
presented by class I and class II MHC molecules, re- 
spectively. The 0t and [3 chains of the TCR are encoded by 
rearranged Vct-Jot-Cct and V[3-D[3-J[3-C[3  gene segments. 
The diversity of TCR is potentially as high as, if not higher 
than that of antibody molecules (1). 
How diverse is the  T  cell response to a  given antigen, 
and  more  precisely,  to  a  given  antigenic  peptide?  This 
question has been addressed by several authors, and various 
class I- and class II-restricted antigens have been used. The 
T  cell response has been found to be very diverse in some 
instances or rather homogenous in others (reviewed in ref- 
erence 2). 
Based on recent work in our laboratory by Cibotti and 
co-workers (3), we make the distinction between the "pri- 
vate" and "public" components of a T  cell response. The 
public  arm of the response is characterized by one highly 
shared  TCR  chain  rearrangement,  reproducibly found  in 
all  or most individuals  with identical genetic background. 
In contrast, the private response involves the seemingly sto- 
chastic emergence ofT cell clones with distinct TCR chain 
rearrangements which vary in different animals. The inter- 
est of such a distinction,  besides the obvious experimental 
advantage  of working  with  cells  that  possess  a  constant 
TCR, is that, in the case of the lysozyme system, public T 
cells appear to be of high aflfinity for their antigen, as sug- 
gested both by their recurrent selection and by their disap- 
pearance upon low expression of lysozyme expressed as a 
self protein in transgenic mice (3). 
In this  context,  we have examined whether  the  T  cell 
response against a tumor-associated antigen derived from a 
nonmutated self protein (encoded in the host genome) in- 
volves a public component. Our model was the P815 tumor 
grafted in syngeneic DBA/2 hosts. P815 is a methylcholan- 
threne induced mastocytoma (4) in which five tumor-asso- 
ciated antigens (A, B, C, D, E) recognized by CTL clones 
have been so far defined (5, 6). The A  and B  antigens are 
epitopes located in the 35-43  peptide  of the P1A protein 
(7).  The latter is not expressed in adult tissues  except testis 
(8, 9).  It is expressed but not mutated in P815 cells (8). We 
show here that two public  I~ chain rearrangements, borne 
by CD8 +  T  cells  specific  for the  A  and  E  antigens,  are 
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cations are discussed. 
Materials  and Methods 
Mice.  Male DBA/2 nfice were raised in the animal facilities 
of the  Institut  Pasteur  or  bought  from  lffa-Credo  (L'Abresle, 
France). BALB/c,  C57BL/6,  C3H/OH,  and SJL/J  female mice 
from  lffa-Credo were bred with male DBA/2  to  obtain the  F1 
mice. Mice were 4-8 wk old at the time of the first tumor inocu- 
lation. 
Cell Lines.  The P815 subline used in this study is the highly 
transfectable clone,  P1-HTR  (10).  P1:204  is  a  P815  antigenic 
variant that does not express the P815 A and B  antigens, but re- 
tains sensitivity to lysis by anti-C and anti-D CTL clones; P1.204 
C+D -, C-D +, and C  D-  have lost the corresponding antigens 
(5).  All retain sensitivity to lysis by anti-E CTL  (6).  L1210-P1A 
was generated by transfection of the L1210 lymphoma (ofDBA/2 
origin), which does not share tumor-specific antigens with P815, 
with a P1A cDNA (6). P815-IL2 was generated by transfection of 
P1-HTR with a plasmid containing the IL-2 cDNA (11).  V2D1, 
V4D6, R56VT, and 15V4T2 are four DBA/2 mastocytoma cell 
lines related to PB-3c (12),  and are a kind gift of Dr.  C. Moroni 
(Institut ffir Medizinische Mikrobiologie der Universit~it, Basel, 
Switzerland). The CTL clones, kindly provided by Dr. Mine van 
Pel  (Ludwig Institute for  Cancer Research,  Brussels,  Belgium), 
have been generated as described in (5) from splenocytes or tu- 
mor-infiltrating lymphocytes (TiLs).l 
Tumor Inoculation and Immunization.  Tumor graft consisted of 
a subcutaneous injection of 106 P815-HTR cells in the right flank 
in 300 bLl of serum-free DMEM.  Naive mice so inoculated pro- 
vided the tumors indicated as growing, 
Preimmunization of the mice against P815 was performed by 
the  subcutaneous injection of 106  P815-IL2  cells  (13).  Except 
where indicated, mice were challenged with 106 P815-HTR cells 
2-4 nlo later.  The  nodules that appeared  transiently after these 
challenges provided the tumors indicated as regressive. 
Oligonudeotides.  Oligonucleotides for repertoire analysis have 
been described previously (14),  except: 
C134: GCCCATGGAACTGCACTTGGC (from 5' to 3' end) 
J[31.2far:  CCTCTATTACCAAAAGCCTGG 
J132.5far: CCTCTAACACGAGGAGCCGAG 
Clonotypic oligonucleotides: 
PIlR:*-GGTGTAGTCGGAGTTICCIGTITCTTGG 
P2IR:*-GTACTGGGTGTCTTGGTTIATIGTITGG 
These oligonucleotides have been devised to hybridize with the 
CDR3  sequences shown in Table  1  (PIIR for J~1.2,  P21R for 
J~2.5).  Since  there  was  some  variability at  the  third  bases  of 
codons in the junctional regions, inosine residues (indicated as I 
above) were incorporated at these positions. The asterisk indicates 
labeling with a ram fluorophore (Applied Biosystems, Inc., Foster 
City, CA). 
Oligonucleotides were  either synthesized on a DNA synthe- 
tizer  (Applied  Biosystems)  or  purchased  from  Genosys  (Cam- 
bridge, UK). 
Direct sequences of V[31 PCR products were made with the 
nested  V]31  S  oligonucleotide:  CTACTTTTACATATATCT- 
GCC. Expression of PIA was tested with the two following oligo- 
1Abbreviations used in this paper: HEL, hen egg white lysozyme; TiL, tu- 
mor-infiltrating lymphocyte. 
nucleotides: P1A-5': CCAGACAAAGCCCACAGTGGC P1A-3': 
GCTTTGCCTGGCTATCCAGGC. 
RNA  Extraction  and  eDNA  Synthesis.  Total  RNA  was  iso- 
lated after ultracentrifugation on a CsC1 cushion according to the 
method described by Chirgwin et al. (15). cDNA was synthetized 
from  10  ~g of RNA,  using a  (dT)17 primer, 25  U  of RNasin 
(Prolnega Corp., Madison, WI) and 10 U  of AMV reverse tran- 
scriptase  (Boehringer Mannheim, Indianapolis, IN)  in the  pro- 
vided buffer. 
PCR and Run-OffProcedure.  All PCRs were performed with 
the following mixture: 25  U/ml of Promega or Bioprobe (Bio- 
probe  Systems,  Montreuil,  France)  Taq  polymerase,  with  the 
provided buffer; MgC12  2.5  raM;  dNTP  0.2 raM;  each primer 
0.5  I~M;  and template (the equivalent of 10-100 ng of reverse- 
transcribed RNA). A 30-bd final vol was used. 40 rounds of am- 
plification consisting each of I  rain at 94~  1 min at 60~  and 
1 rain at 72~  were performed. 
The run-off protocol is similar, with the  following modifica- 
tions: a single dye-labeled primer is used, at the concentration of 
0.1  ~M; the template is 2  btl of PCR product for a  10 txl final 
vol, and one to six cycles of elongation are performed, depending 
on the yield of the PCR. Annealing temperature was 60~  for all 
primers except PIlR for which it was 65~ 
Repertoire Analysis.  The  technique of repertoire  analysis has 
been  described  in  (16).  Briefly,  a  PCR  is  performed  on  the 
eDNA  of interest  using  a  V]3-specific  primer  with  the  C[34 
primer. (To cover the full repertoire, 21  such reactions, using the 
primers specific for the 21 functional V]3 segments of DBA/2, are 
made.)  The PCR product is then subjected to run-off reactions 
using nested dye-labeled primers, specific either for C]3 or one of 
the 12 functional J~ segments. This run-off product is run on an 
automated sequencer, together with size  standards; the  intensity 
of the various bands is recorded, then analyzed with the Immuno- 
scope |  (developed by Christophe Pannetier) software, which also 
provides the lengths of the DNA fragments. The  repertoire  ob- 
served with peripheral T  cells  of a naive inouse (for ai  W V~-J]3 
combination) is a highly reproducible gaussian-shaped profile with 
3-bp spaced peaks corresponding to in-flame sequences (14,  16). 
Direct Sequence qf PCR Products.  The sequence was performed 
using the Sequenase 2.0 kit (U.S. Biochemical Corp., Cleveland, 
OH) and 35S-labeled dATP (Amersham Corp., Arlington Heights, 
IL), according to the technique described by Casanova et al. (17). 
The template is the product ofa 100-pxl PCR performed with the 
relevant V[B and J]3 primers, after purification by nfigration on a 
ethidium bromide-stained 2% agarose gel, excision of the specific 
band, electroelution, and ethanol precipitation. 
Public  Clones Quantification.  We  quantify the  proportion  of 
mRNAs coding for a TCR with a public CDR3 sequence in the 
total mRNAs coding for TCRs sharing V]3 andJ[3 segments (but 
with any CDR3 sequence) by the following procedure. To mea- 
sure the V131-J]31.2 clone, the cDNA from the sample of interest 
is subjected to  a PCR  using the V]31 and J]31.2far  primers, the 
product of which is separated into two equal aliquots. The total 
population is then revealed by performing a run-off reaction on 
the first  aliquot with the faro-labeled J131.2 primer, which yields 
126-147-bp-long  fluorescent  products.  The  specific  sequence 
products are revealed in a run-off reaction on the second aliquot 
with the ram-labeled PIIR clonotypic primer, whose  result is a 
113-bp-long fluorescent  product.  (To  measure  the  V131-J]32.5 
clone, the procedure is identical, except for the following differ- 
ences: in the initial PCR, the V131 and J132.5far primers are used; 
in the run-off on the first  aliquot, the fam-labeled J]32.5  primer, 
which yields 118-139-bp-long product, is used; in the run-offon 
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also  a  ll3-bp long product, is used.) The two run-off products 
are mixed in equal amounts, then loaded in the  automated se- 
quencer.  The  ratio  of the  fluorescence intensity of the  113-bp 
band to  the sum of the other bands indicates the proportion of 
the specific sequence in the total (after  correction of the specific 
activities of the primers). The background, as measured either on 
the polyclonal population of a naive mouse or on a cloned tem- 
plate with a CDR3 of right size but wrong sequence, is ~3%. 
To estimate the percentage of V[31 § T  cells in tumors, a fully 
quantitative PCR protocol, already described in (18) and (19), has 
been used. Briefly, it consists of the coamplification in the same 
PCR tube and with the same primers, of the cDNA of interest 
and of a known number of copies of a standard plasmid that con- 
tains the  sequence amplified from cDNA, with a 4-bp deletion 
somewhere  in the middle (not in the primer regions). Both se- 
quences  are  amplified with  the  same yield up  to  saturation. A 
run-off reaction is then made on this PCR product using a dye- 
labeled, nested primer. This product is run on an automated se- 
quencer: the products of the cDNA and standard plasmid are sep- 
arated on account of the  4-bp size  difference. The  ratio  of the 
amount of wild-type sequence with the amount of standard se- 
quence is determined with the Immunoscope  |  software. The ac- 
curacy of the measurement is controlled by using a serial dilution 
of standard plasmid, checking that the yield is linear. The median 
result from standard/wild type ratios in the range from 0.1 to 10 
is taken as the final number. 
How Cytometry.  Cell populations were analyzed on a FACS  | 
using  the  FACScan  |  (Becton  Dickinson  and  Co.,  Mountain 
View,  CA)  software.  Cells  were  incubated with  FITC-conju- 
gated  anti-CD8  mAb  (YTS  169.4;  Caltag  Laboratories,  South 
San Francisco, CA), PE-conjugated anti-CD4 mAb (YTS 191.1; 
Caltag), and dead cells were excluded by propidium iodide incor- 
poration. 
Panning.  8-cm diameter polystyrene plates were coated with 
mouse  anti-rat Ig  (H+L)  polyclonal antibody (Jackson  Immu- 
noresearch Laboratories, Inc., West Grove, PA). Cells were then 
added in PBS 2% FCS, after their incubation with either the anti- 
CDS-FITC or the anti-CD4-PE mAb indicated above. After 70 
min of incubation at 4~  the nonadherent population was har- 
vested by three gentle washes with PBS 2% FCS. The adherent 
cell population was  then collected using a  silicone cell scraper. 
The cells were then incubated with the second antibody and the 
purification level estimated by FACS  ~ analysis. 
Results 
Analysis of TiLs.  Two groups of DBA/2  mice were in- 
jected  subcutaneously  with  106  P815  cells.  In  the  first 
group,  composed  of initially naive mice,  steadily growing 
tumors developed,  causing death  after ~30  d.  The second 
group contained DBA/2 mice preimmunized with 106 P815- 
IL2  cells,  a  procedure  known  to  vaccinate mice  against a 
subsequent  challenge  with  P815  cells  (11).  When  P815 
cells were  similarly grafted  onto  these  immunized mice,  a 
small tumoral nodule developed for ~1  wk, then stabilized 
and disappeared in ~3  wk. 
Tumors and spleens of naive and preimanunized individ- 
ual mice  were  taken  2  wk  after  P815  tumor inoculation. 
RNA  was  extracted,  reverse-transcribed into  cDNA,  and 
T  cell repertoire analyses were carried out as described pre- 
viously (16). Briefly, PCR  reactions were performed with a 
C~-specific and each V~-specific oligonucleotide, and ali- 
quots were subjected to run-offreactions initiated with flu- 
orescent J~  or  CI3-speciflc  oligonucleotide  primers.  The 
fluorescent  elongation  products  display  different  lengths 
because  of differences in their CDR3  regions.  They were 
size-fracionated in an automated DNA  sequencer and the 
fluorescence intensity in each peak was recorded. 
Results are  shown in Fig.  1  for four representative VI3s 
and  three  mice  from  each  group.  The  peripheral  (spleen) 
repertoire of the tumor-bearing mice does not notably dif- 
fer from that  of control mice, with rare  exceptions of mi- 
nor peaks (Fig.  1, mouse 4, V[38.1). The repertoire of TiLs 
is  strikingly  different  from  this  steady  pattern.  For  most 
mice with I #1  growing 
tumors  #2 
#3 
mice with I  #4  regressive 
tumors  #5 
#6 
control mouse 
S 
T 
T 
T 
S 
T 
T 
T 
S 
V[31  V~8.1  V[310  V~11 
5  7  7  9  11  13  5  7  9  11  13 
CDR3 size (aminoacids) 
.....  i 
9  11  13  5  7  9  11  13 
Figure  1.  Repertoire  of ot/[~ T  cells in 
the tumors or the spleens of individual tu- 
mor-beating mice, for a few representative 
V[3  segments.  Total  RNA  was  extracted 
from spleen (S) or tumor (7)  of individual 
mice  bearing  growing or  rejected  tumors 
(see text).  After  reverse  transcription  into 
cDNA, V[3-C[3 PCR reactions were  per- 
formed with the various V[3-specific prim- 
ers, labeled with a nested fluorescent C[3- 
specific primer,  and size-fractionated in an 
automated  DNA  sequencer.  (Horizontal 
axis)  Size in  amino-acids  of the  CDR3 
junctional region as defined by Chothia  et 
al.  (20) deduced  from  the  fragment  size. 
( Vertical axis) Fluorescence intensity, in arbi- 
trary units. A naive DBA/2 mouse has been 
included as a control. 
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JI31.2 (A) or VI31-JI32.5 (B) PCR prod- 
ucts from  tumor  samples or  a control 
DBA/2 spleen. 
Vl3s,  only a few peaks are observed. We directly sequenced 
several  PCR  products,  which  yielded  single  peaks.  The 
junctional region was readable  and unambiguous,  strongly 
suggesting that such peaks correspond to clonal expansions. 
Thus,  as previously observed in humans  (21-24),  TiLs ap- 
pear to be oligoclonal. In the case ofP815,  our data (Fig.  1 
and not shown)  lead to  the  estimate that  the  TiL popula- 
tion in one mouse contains 100-300 T  cell clones. 
These oligoclonal patterns  are highly variable in distinct 
animals.  Dominant  peaks  on  V[3-C[~  profiles are  not  ob- 
served at the same  CDR3  length in all animals and recur- 
rent peaks  in two or more animals  correspond .most often 
Table 1.  Sequences  of V[J1-J~l.2  and V~1-J~2.5 TCRJunctional Regions Read  from PCR Products Obtained  from Tumor Samples, and 
Deduced Amino Acid Sequences of the CDR3. 
Junctional  Amino acid 
Mouse  V~  J[3  Length  V~3 End  region  J~3 Beginning  sequence 
1  1  1.2  9  AGC CA  A GAG ACG GGS  AAC TCC GAC TAC 
2  1  1.2  9  AGC CA  A GAR ACG GGG  AAC TCC GAC TAC 
3  1  1.2  9  AGC CA  A GAA ACR GGS  AAC TCC GAC TAC 
4  1  1.2  9  AGC CA  A GAG ACR GGR  AAC TCC GAC TAC 
5  1  1.2  9  AGC CA  A GAG ACS SGG  AAC TCC GAC TAC 
6  1  1.2  9  AGC CA  Unreadable  Unreadable 
Spleen  1  1.2  9  AGC CA  Unreadable  Unreadable 
1  1  2.5  9  AGC CA  G ACA ATT  AAC CAA 
2  1  2.5  9  AGC CA  A ACA ATT  AAC CAA 
3  1  2.5  9  AGC CA  A ACA ATT  AAC CAA 
4  1  2.5  9  AGC CA  R  ACA ATT  AAC CAA 
5  1  2.5  9  AGC CA  R  ACA ATT  AAC CAA 
6  1  2.5  9  AGC CA  R  ACA ATT  AAC CAA 
Spleen  1  2.5  9  AGC CA  Unreadable  Unreadable 
GAC ACC CAG 
GAC ACC CAG 
GAC ACC CAG 
GAC ACC CAG 
GAC ACC CAG 
GAC ACC CAG 
SQETGNSDY 
SQETGNSDY 
SQETGNSDY 
SQETGNSDY 
SQETGNSDY 
and SQETRNSDY 
Mix 
Mix 
SQTINQDTQ 
SQTINQDTQ 
SQTINQDTQ 
SQTINQDTQ 
SQTINQDTQ 
SQTINQDTQ 
Mix 
Positions where two nucleotides could be read are indicated as follows: R  = A or G; S =  C or G. Sequences are available 
sion numbers U44406 to U44416. 
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in Genbank under acces- to different J[3  segments  (not shown).  There  is,  however, 
one exception: as can be seen in Fig.  1, in all analyzed tu- 
mors, a prominent peak is found in the V131 profile with a 
CDR.3 length of nine amino acids. J[3 analysis revealed the 
usage of two J[3s in this peak: J[32.5 in .all samples and J[31.2 
in five out of six. 
Recurrent V~1-J~1.2 and V~81oJ~82.5 Sequences in Different 
Individuals.  We directly sequenced the PCR products ob- 
tained with oligonucleotides specific for V131 and J[31.2 or 
J[32.5 from a number of TiL samples (Fig. 2, Table 1). In all 
samples but one (mouse 6, J131.2),  sequences were readable 
in the CDR.3 region and, as anticipated, in-frame TC1L se- 
quences with a CDR.3 length of nine amino acids could be 
deduced from the  sequences.  In some  cases,  two  nucleo- 
tides could be read at the same position. This was no PCP, 
artifact since the same phenomenon was observed with two 
independent PClK products.  It indicates  that a few clones, 
with  almost  identical  TCR13  sequences,  are  present  to- 
gether  in  the  same  tumor.  Amino  acid  sequences  were 
identical  among different  individuals,  or  among  different 
sequences  in the  same individual  (with  one partial  excep- 
tion,  mouse 5, J131.2)  despite  a few differences  in the nu- 
cleotide  sequences.  These  amino  acid  sequences  corre- 
spond to those of CTL clones obtained by one of us after in 
vitro expansion of splenocytes from a single individual  (6). 
These two recurrent rearrangements will,  from now on, 
be called public rearrangements, and it will be assumed that 
each correspond to one or a few public T  cell clones, even 
though the  corresponding ix chain rearrangements  remain 
unknown. 
Increased Frequency of  T  Cells Using the  Public TCR[3 
Chains  Is  Observed in  Peripheral T  Cells of  Tumor-bearing 
Mice.  As  mentioned  above,  the  peripheral  repertoire  of 
tumor-bearing animals and of controls look similar (Fig.  1). 
This indicated that analysis of V[3-J[3 profiles was not quite 
sensitive enough to detect the clonal expansion or the accu- 
mulation of public T  cells in the periphery of tumor-bearing 
animals.  This  problem,  however,  could  be  overcome by 
the  use  of "clonotypic" oligonucleotides.  Knowing the  t3 
chain sequence of public  clones, we devised more specific 
oligonucleotides,  penetrating within  the  CDR3  region,  as 
described by Cochet  et  al.  (16).  To  cope with  the  previ- 
ously  mentioned  nucleotide  variations,  inosine  residues 
were incorporated at certain positions, as described in Ma- 
terials  and  Methods.  Using  two  such  primers,  we  found 
both  public  13  rearrangements  in  splenocytes,  PBL,  LN 
cells, but not thymocytes (Fig. 3 represents the results with 
the V[31-J[32.5 rearrangement  for a mouse in which these 
public  cells  were  particularly  frequent  in  the  periphery). 
Thus,  public  T  cells  observed  among  TiLs  can  also  be 
found in the periphery. 
The Frequency of Public T Cells in Either Spleen or Tumor Is 
Higher in  Secondary than in  Primary Responses, Although  No 
Obvious Correlation Can Be Made with Tumor Rejection.  As 
we  did  not  anticipate  finding  a  similar  response  in  mice 
with  growing  and  rejected  tumors,  we  used  quantitative 
PCR. techniques to measure the size of the public clones in 
these mice,  using the same cDNAs as above. Results,  dis- 
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Figure  3.  Detection of the tumor-specific T  cells in various organs of a 
tumor-bearing mouse. The  tumor-rejecting mouse has been immunized 
with P815-IL2, challenged with P815 6  wk later, and analyzed 14 d  after 
the challenge. The control mouse is a naive DBA/2 mouse. A PCP, with 
the V[31 and J132.5-far primers has been performed on the cDNA ob- 
tained from the organ. This product was separated into two equal ali- 
quots: one was used as a template for the elongation of a fluorescent 
l[32.5-specific primer, providing the peaks on the right part of each panel. 
The other was used in the elongation of the clonotypic P211L primer, 
providing the single peak on the left. These two run-off products were 
then mixed and size-fractionated in an automated sequencer (see Materi- 
als and Methods, Public  Clones Quantification,  for more details). 
played in Fig.  4,  show that,  either in the spleen  or in the 
tumor itself,  the public T  cells are more frequent in tumor- 
rejecting mice than in those bearing growing tumors.  The 
sum of the populations of both clones has to be considered, 
since the response can be strongly biased toward one or the 
other kind of clone. 
Since public  T  cells  arise  and  are  detectable  during the 
primary  response  to  the  P815  tumor,  we  tested  whether 
the presence of one or the other clone had an effect on the 
growth of the tumor.  To do so, we took advantage of the 
fact that in a few occurrences, naive DBA/2 mice reject a 
usually lethal P815 graft. We bled a group of initially naive 
mice inoculated subcutaneously with  106 P815 cells at day 
14  after  the  graft,  when  it  was  not yet possible  to  know 
whether they would reject  the tumor or not.  The tumors 
were then regularly followed. We compared the amount of 
public cells found in the blood of three mice that finally re- 
jected their tumor, one with only a transient rejection, and 
six  with  the  usual  steady  tumor  growth.  Results  are  dis- 
played in Fig. 5: as can be observed, no correlation can be 
established  between  subsequent  rejection  and  amount  of 
public cells at day 14 in blood. 
Public Clones Are  Specific for  Two  Antigens  of P815  In 
Vivo.  CTL clones derived in vitro by one of us, with the 
two public TCRs,  are specific for the P815 A  and E  anti- 
gens (6). To check if this specificity is the same for the pub- 
lic  cells  observed  in  Vivo,  we  investigated  whether  they Figure  4.  Frequencies  of  public  cells  in  the 
spleen  and  tumors  of tumor-bearing mice.  The 
percentage of public T cells among the V131-J[31.2 
or  v131-J]32.5 populations  was  measured  as  ex- 
plained in the legend to Fig. 3. The percentage of 
V131-J[31.2 and V131-J]32.5 among total V]31" ceils 
was  measured  in a  similar way, with  a  V]31-C[~ 
PCR followed by run-offs with  C13-,  J]M .2-,  and 
J~2.5-specific  fluorescent  primers  of known spe- 
cific activities. Finally, the frequency  of V]31 + T 
cells in the tmnors was estimated by the measure of 
V131 and hypoxanthine  guanine ribosyl transferase 
transcripts by quantitative PCR as described in Ma- 
terials and Methods.  Public clone: [~, v131-J[31.2; 
at, V]~ 1-J[32.5. 
emerge  in  the  repertoire  of mice  immunized with  either 
P815  variants,  a  P1A  transfectant,  or  other  mastocytoma 
lines (Table 2). 
The public V~1-J~1.2 rearrangement was observed after 
immunization by  P815  but  not  by  P1:204,  a  variant  of 
P815  that  expresses  antigens C, D,  and E,  but has lost AB 
expression  (5,  6).  The  Vi31-J~l.2  public  clones  are  thus 
specific in vivo for a PlA-derived antigen, as confirmed by 
the fact that it is elicited by the L1210-PIA transfectant. It 
is worth noting that this public response was observed only 
in two-thirds  of the  mice responding to  P815,  even upon 
secondary immunization. 
Cells harboring the V[31-Jf32.5 TCR  are not specific for 
a  P1A  product  since  they  arise  in  response  to  P1:204. 
They  are  specific  for  neither  the  P815  C  nor D  antigens 
because they also arise in response to the corresponding an- 
tigen-loss variants.  Since  they  are  not  elicited  by  L1210- 
P1A or the other DBA/2  mastocytoma cell lines, they are 
specific  for  a  P815  antigen  not  shared  with  these  tumor 
lines  (thus  excluding  a  mast  cell  differentiation  antigen). 
The  only characterized antigen ofP815  that remains is the 
E  antigen for which the corresponding loss variant was not 
available. 
Since we  found one occurrence  of a  response  with  the 
VI31-J[31.2  public  TCR  against  the  15V4T2  line,  we 
checked whether the four PB-3c-derived cell lines (12) ex- 
pressed  P1A in vivo,  by PCR  with PlA-specific oligonu- 
cleotides on cDNA  obtained from the solid tumors. V4D6 
and 15V4T2 were  found to  express P1A mRNA  (in three 
samples out of three), in contrast to V2D1  and R56VT. Al- 
though  three  samples  are  not  statistically  significant,  our 
data suggest that 15V4T2 and V4D6, although they express 
PIA mRNA,  are less e~cient than P815 or L1210-P1A to 
generate anti-P815A CTL responses in vivo. 
Public Clones Are CD8 § In  ￿88  To determine whether 
the two types of public T  cell clones express CD4 or CD8 
Figure 5.  Measurement  of the size of public clones in 
the blood of mice 14 d after graft of a P815 tmnor and sub- 
sequent outcome of the graft. Naive DBA/2 mice were in- 
jected  with  1if'  P815  cells subcutaneously.  At  day  14, 
when all possessed a tumor nodule, they were bled at the 
base of the  tail, and cDNA was  synthetized  from  these 
blood samples. Public clone quantification was then per- 
formed as explained in the legend to Fig. 3. The size of the 
tumor nodule was then regularly checked. Although most 
mice were dead at day 30 after a steady growth  of the tu- 
mor  (indicated  by  the  up-pointing arrow),  the  nodule 
spontaneously regressed in four nfice, three  up to  disap- 
pearance (down arrow), one only transiently (down and up). 
~, V~1-J/81.2; I, v[31-JI32.5. 
444  Recurrent TCR Rearrangements in the CTL Response Table 2.  Occurrences  of Public T  Cells in Response to  Various 
Tumors. 
Occurrences  Occurrences 
of public  of public 
Type of  Tested  clone  clone 
Cell line  response  tissue  VI31-J[31.2  V~ 1-J[32.5 
P815  Primary 
Primary 
Secondary 
P1.204  Primary 
P1.204 C+D-  Primary 
P1.204 C-D+  Primary 
Pl.204 C-D-  Primary 
L1210-P1A  Primary 
V2D1  Primary 
V4D6  Primary 
1K56VT  Primary 
15V4T2  Primary 
Tumor  5/6  6/6 
Blood  7/11  11/11 
Tumor  4/6  6/6 
Tumor  0/4  4/4 
Tumor  0/3  3/3 
Tumor  0/3  3/3 
Tmnor  0/3  3/3 
Tumor  5/6  0/6 
Tumor  0/3  0/3 
Tumor  0/3  0/3 
Tumor  0/3  0/3 
Tumor  1/3  0/3 
Mice were analyzed 14 d after the subcutaneous inoculation of 106 tu- 
mor cells in naive (,primary responses) or P815-1L2-vaccinated  (second- 
ary responses) DBA/2 mice. Public clone quantification (see Materials 
and Methods)  was performed on cDNA from TiL or PBL of individual 
mice as indicated,  cx/[3 T cell infiltration was observed in all cases. In a 
given Vf3-J[3 subpopulation, the mean value and standard deviation of 
the background level of public/total TCIK ratio measure has been cal- 
culated  on three naive DBA/2 PBL samples. Measures falling within 
the range of this mean value +  1 SD were considered  as negative. All 
positive measures were above mean value +  3 SD. 
coreceptor  molecules  in  vivo,  we  immunized mice  with 
P815 IL-2 and inoculated them several times with P815 to 
expand the specific T  cells. Splenocytes taken 14 d after the 
last challenge were enriched in CD4- or CD8-positive cells 
by panning. The  degree  of enrichment was  measured  by 
flow  cytometry,  and public clones were  quantified in the 
samples as above. Fig. 6  shows that T  cells with the public 
VJ31-J[32.5  rearrangement segregate with the CD8 marker, 
demonstrating that at least most of these cells are CD4-CD8 + 
in vivo. Comparable results have been obtained with both 
public clones and in several mice.  This result is consistent 
with the specificity of these T  cells, since CTL are usually 
CD8 + and P815 is MHC  class II-negative (not shown). 
Presence of Public and Private  T  Cells in a Panel of  Anti-P815 
CTL  Clones.  We  also  sequenced the  TCR  [3  chain in a 
panel of in vitro-derived P815-specific CTL clones (Table 
3).  Two  clones,  P1:5  and  3I(5),  obtained from  different 
mice,  both specific  for  a  P1A product,  used  the  V[31  and 
J[31.2 segments, with the CDR3  sequence of public cells. 
The  other  sequences  from  this  panel  were  found  only 
once  (TiL3III(16) and -3III(18) share exactly the same se- 
quence but arose in the same mouse and are likely to be sis- 
ter  clones).  We  looked  in  the  TiL  repertoires  of several 
P815  tumor-bearing mice for prominent peaks sharing the 
same V[3  segment and CDR3  length, but we  did not find 
any.  These  CTL  clones are  thus very likely to  be private 
clones. 
The  Public  Responses  Are  Observed  in  F1  Animals  with  a 
DBA/2  Parent.  Humans are usually heterozygous at their 
different  MHC  loci.  The  presence  of these  other  alleles 
may greatly influence the  available repertoire  restricted to 
one given allele, precluding the emergence of a public re- 
total population 
(CD4/CD8 = 2,4) 
9 
CD4+ enriched population 
(CD4/CD8 = 24,9) 
9 
clonotypic  J[~-specific primer 
primer 
CD8+ enriched population 
(CD4/CD8 = 1,0) 
9 
CDR3 size (aminoacids) 
0 
e~ 
t~ 
Figure 6.  Public T cells segre- 
gate with the CD8 marker. Pub- 
lic clone quantification has been 
performed,  as  explained  in  the 
legend to Fig. 3, on splenocytes 
from an immunized mice sorted 
by panning (see details in text). 
Results for the VJ31-J[32.5 public 
sequence  are  shown  here.  The 
CD4/CD8 ratio, as measured by 
flow cytometry  before and after 
the panning, are indicated above 
each panel. Indicated is the ratio 
of the area of the sequence-spe- 
cific peak indicated by the arrow 
with the sum of the areas of the 
other peaks for the whole popu- 
lation. 
445  Levraud et al. Table 3.  Sequences  of the CDR3 Regions of P815-specific CTL Clones 
CDR 3  Junctional  Amino acid 
CTL clone  Antigen  V[3  JI3  length  V[3 3'  region  J[3 5'  sequence 
P1:5  A  1  1.2  9  GCC AGC AGC CA  A GAG ACG GGA  AAC TCC GAC TAC  SQETGNSDY 
P35:10  B  2  1.1  5  AGT GCC  ACA GGG C  CA GAA GTC  TGPEV 
TiL 3I (4)  AB  5.2  2.7  7  GCC AGC TCT  CCC GGG G  CC TAT GAB+  CAG  SPGAYEQ 
TiL 3I (5)  AB  1  1.2  9  GCC AGC AGC CA  A GAA ACA GGG  AAC TCC GAC TAC  SQETGNSDY 
TiL 3III (16)  AB  10  1.1  8  GCC AGC AGC  CAC AAT G  CA AAC ACA GAA GTC  SHNANTEV 
TIL 31II (18)  AB  10  1.1  8  GCC AGC AGC  CAC AAT G  CA AAC ACA GAA GTC  SHNANTEV 
P1.515  C  6  1.3  10  GCC AGC A  TC TCC GGG ACA TT  T TCT GGA AAT ACG GTC  ISGTFSGNTV 
P1.204:8  D  10  2.7  7  GCC AGC AGC  TCG CAA AAA  TAT GAA CAG  SSQKYEQ 
RNA has been extracted directly from a frozen vial of cells, cDNA synthetized, and V[3-C13 PCt( reactions performed with the functional Vf3-specific primers. Positive 
reactions were confirmed, and their product directly sequenced with the CI35' primer. Only the productive rearrangements obtained are displayed. The two first codons 
displayed under V[3 3' do not belong to the CDR3 region as defined in (20) but have been shown for clarity; they are not included in the amino acid sequence. Antigen 
indicated as AB means specificity for a P1A product (i.e., lysis of L1210-P1A but not ofL1210). Sequences are available in Genbank under accession numbers U44417 
to U44424. 
sponse observed in homozygous individuals. To mimic this 
situation, we analyzed whether the public response against 
P815  is maintained in F1 animals, derived from a cross be- 
tween DBA/2 and either BALB/c (H-2d), C57B1/6  (H-2b), 
C3H/OH  (H-2k),  or SJL/J  (H-2  s)  mice.  As expected, tu- 
mors grew in F1 mice, but not in parental strains other than 
DBA/2.  The tumors ofF1 mice were taken at day 14 and 
the repertoire of TiLs searched for the public TCRs, using 
the  clonotypic  primers.  The  two  rearrangements  were 
found in all F1 hybrids. Thus,  there is no negative effect of 
the other MHC  alleles on the public response against P815. 
We wondered whether the two public T  cell clones seen 
in DBA/2 would be detectable in BALB/c mice, which are 
also of H-2  d MHC  haplotype. In BALB/c mice, the tumor 
does  not  grow,  implying that  an  immune  response  is  di- 
rected  against  minor  histocompatibility  differences  with 
DBA/2.  It  may  thus  not  be  surprising  that  the  public 
TCRs  were  not  detected in  the  spleens of BALB/c mice 
14 d after P815 inoculation. 
Discussion 
We have studied the repertoire of TiLs in DBA/2 mice 
grafted  with  the  P815  mastocytoma  tumor  cell  line  in 
which  five  tumor-specific  antigens,  A,  B,  C,  D,  and  E, 
have been identified (5, 6). We found that the TiL popula- 
tion is ohgoclonal, containing a few hundred clones, most 
of which do not reproducibly emerge in all tumors.  How- 
ever,  two  TCtL[3  chain  rearrangements,  with  CDR3  se- 
quences  entirely  conserved  at  the  amino  acid  level,  oc- 
curred in most or all animals. A  V[31-J[31.2 rearrangement 
was found in ~70%  of the P815-bearing mice, in primary 
or  secondary responses.  A  V[31-J[32.5  rearrangement  was 
detected  in  100%  of the  samples.  Cells  with  both  TCR 
types  were  of  CD8  phenotype  and  could  be  detected 
among TiL and in the peripheral lymphoid compartments 
of tumor-bearing  mice.  CTL  clones  with  corresponding 
TCR  rearrangements, derived from splenocytes of a single 
mouse,  have  been  recently  described  by  one  of us;  the 
specificity of the V[31-J[31.2 cells was attributed to a prod- 
uct of the P1A gene, and that of the V[31-J[32.5 cells to the 
P815E  antigen  (6).  Using  antigen-loss variants  and  other 
tumor  lines, we  find a  fully compatible specificity of our 
public T  cell clones in vivo. Furthermore,  the V[31-J[31.2 
public  rearrangement  was  found  to  be  borne  also by the 
P1:5  CTL  clone,  the  epitope  of which  has  been  exten- 
sively characterized as being the 35-43 peptide of PlA pre- 
sented by L a (7), particularly its LeuV-Val  8 residues (25). It is 
highly likely that public V[31-J[31.2 cells, even though their 
TCR  ix chain is not known, recognize the same epitope in 
vivo. 
Analyzing TCR  use in vivo, at the tumor site or in the 
periphery, we found T  cells specific for P815A in 70%  of 
mice, specific for P815E  in  100%  of the mice. Some mice 
displayed  a  substantial  amount  of both  types  of  clones, 
whereas others were  strongly biased in favor of only one. 
Brichard et al., measuring cytotoxic activity of splenocytes 
after 7 d of in vitro culture, detected activity against the AB 
antigens  in  50%  of the  mice,  against  CDE  in  85%  (6). 
There  again,  the response could be  evenly distributed be- 
tween the two types of effectors or strongly biased. Thus, 
similar conclusions can be  reached with  two  independent 
sets  of data  obtained with  very different  techniques.  The 
larger amount  of responsive individuals in  this  report  can 
be explained in several ways. First, the two techniques may 
differ in sensitivity. Second, T  cells with the public TCR  [3 
chain in vivo may not always be specific for the A  or E  an- 
tigens,  since  their ix  chain  is  not  known;  however,  given 
TCR  diversity, this is extremely improbable. Nevertheless, 
some of these public T  ceils detected by PCR may be non- 
cytolytic  (as  discussed later).  Third,  immunization  proto- 
cols are not exactly the same,  but this is not the only rea- 
son, since we observed that the protocol used in (6) yielded 
too a 100% occurrence of public anti-E T  cells (on 16 sam- 
446  Recurrent TCR Rearrangements in the CTL Response ples, not shown). Finally, it is possible that in vitro culture 
somehow modifies the response, perhaps increasing the ini- 
tial bias between the clones. 
Infiltration by T  cells bearing these recurrent TCRs can 
be observed in  growing as well as in regressing P815  tu- 
mors.  In other terms,  there is  no obvious correlation be- 
tween tumor rejection and the occurrence of the two public 
clones known to correspond to cells  with a demonstrable 
specific cytolytic activity in vitro. Quantitatively, however, 
there is a significant difference between regressing tumors 
grafted onto preimmunized mice and tumors growing onto 
naive  mice,  if one  considers  the  frequency of the  pubhc 
cells  either in the tumor itself or in the peripheral organs. 
This, however, does not prove that the stronger prohfera- 
tion of such cells is associated with tumor regression, since 
it is a usual feature of a secondary T  cell response that it is 
stronger than the primary one.  It does indeed validate, in 
the context of the anti-P815 response, a quantification tool 
already put to the test in other systems like the response to 
pigeon cytochrome C  (16).  Contrary to our expectations, 
our attempts to find a link between the amount of public 
T  cells  among PBL in  a primary response and the  future 
evolution of the tumor have so far failed to reveal any ob- 
vious correlation. Three interpretations can be proposed: 
First,  public cells may be elicited by the tumor cells, but 
have no relevance for tumor rejection in vivo, the cytotox- 
icity of corresponding CTL clones being mainly a conse- 
quence of in vitro culture conditions. Arguing against this 
possibility is the crucial role exerted by anti-P1A CTLs in 
vivo, evidenced by the emergence of a P1A-loss variant in 
vivo after nearly total tumor rejection (5). It remains possi- 
ble that the anti-P1A CTLs active in vivo bear TCRs dif- 
ferent from the public one, but it would be hardly explain- 
able. The public cells may also constitute only a very small 
fraction of the  anti-P815  CTLs in vitro, which would be 
subject to stochastic fluctuations. Although this is possible, 
in the one mouse analyzed by Brichard et al. for which this 
question  can  be  answered,  such  cells  constituted  all  the 
clones obtained (6). 
A  second hypothesis, frequently put forward to explain 
the growth ofimmunogenic tumors, is that CTLs are elic- 
ited normally by the tumor cells, but come too late, at too 
slow a division rate to cope with a fast-growing tumor. Al- 
though this may explain why pubhc T  cells  are present in 
growing tumors, this hypothesis seems ruled out by our ex- 
periment in which the early population of public cells was 
compared  to  the  tumor  outcome  (Fig.  5).  Furthermore, 
previous  data  provide  some  evidence  that  other  mecha- 
nisms take place at later stages.  Indeed, although it may not 
be an accurate picture of the events taking place at the tu- 
mor site, it has been observed that P815-specific immunity 
in splenocytes increases in the first 10 d or so after inocula- 
tion  of P815  in  syngeneic hosts,  then  decreases  as  tumor 
growth proceeds (26,  27). 
The third interpretation, which we favor, is that the bio- 
logical  activities  of P815-specific  T  cells  are  different  in 
mice bearing growing  or regressive tumors.  For instance, 
these  cells,  primed  under  optimal  conditions  during  the 
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immunization step with P815-IL2, could be effector CTLs 
in rejected tumors. In growing tumors, their first encounter 
with their antigen in the absence of suitable costimulation 
and/or growth factors may have induced  anergy,  or even 
negative  regulatory  functions.  We  are  currently  testing 
these hypotheses. 
A recent study from our group of the T  cell response to 
hen  egg white  lysozyme (HEL)  led  us  to  this  distinction 
between public (i.e., recurrent) and private (i.e., nonrecur- 
rent  and  apparently stochastic)  clones  (3).  We have been 
able to find a public  response,  characterized by the VI31- 
J131.2  rearrangement,  against  a  self protein,  namely P1A, 
which  has been shown  to  be a genuine,  nonmutated  self 
protein  (8).  The  second  rearrangement  (V131-J[32.5)  in- 
volves the E antigen which has yet not been cloned. 
In addition to the two public responses, are there private 
responses against P815, and more precisely against products 
of P1A?  We  have  sequenced  six  in  vitro-isolated  CTL 
clones which are specific for a P1A-derived peptide, out of 
which  two  display the public  rearrangement and four do 
not (Table 3). We searched the sequences of the latter with 
clonotypic primers in several TiL samples and did not find 
them  (data  not  shown).  These  sequences  are  thus  very 
likely to belong to private clones. The TiL are oligoclonal 
and their pattern is, for most of the peaks, nonrecurrent in 
different  samples.  Whether  all  nonrecurrent  peaks  corre- 
spond to private specificities or whether some (or all) result 
from some random, nonspecific local expansions, cannot be 
assessed without further experiments. 
We  propose  to  divide  tumor  T  cell  epitopes  derived 
from self proteins  into  two  categories:  those  which,  like 
P815A  or  E  antigens,  elicit  public  responses,  and  those 
which  elicit  only private  responses  (like,  maybe,  P815C 
and D). A plausible reason for the absence of a public arm 
against the latter may be the fact that they are expressed at 
low levels in the thymus or in tissues  normally accessible to 
T  cells.  This would fit with the observation that, in HEL- 
transgenic mice, the public, but not the private, arm of the 
anti-HEL T  cell response is deleted when HEL is expressed 
at low levels  (3).  Similarly,  the  self antigens  for which  a 
pubhc response has been observed so far are derived from 
proteins expressed only in tissues isolated from T  cell circu- 
lation, like the testis  for P1A (8,  9)  or the central nervous 
system for the myelin basic protein (28). 
Along  this  hypothesis,  one  can  hope  to  find  a  public 
component in the response to human melanoma antigens 
derived from nonmutated self proteins like members of the 
MAGE family or BAGE, which have an expression pattern 
similar to P1A (i.e.,  in testis and placenta) (9, 29-31). Con- 
versely,  antigens  derived  from proteins  like  tyrosinase  or 
melan-A, which are expressed by normal melanocytes (32, 
33) might elicit only private, rather than pubhc, T  cell  re- 
sponses. We are currently searching public responses in hu- 
man melanoma infiltrating lymphocytes. 
We wondered whether the occurrence of public T  cell 
responses would be more easily observable in  a  homozy- 
gous as opposed to a heterozygous MHC background, the 
latter being the usual rule in humans. This was not the case since the two public anti-P815 clones were observed in all 
tested combinations.  Furthermore, public T  cell responses 
against viral antigens  have  been  reported in  humans  (34-- 
36). It is thus not unlikely that our speculations hold true in 
the human situation. 
Conversely, no  public anti-A or anti-E  cells have been 
observed when P815 was grafted onto BALB/c mice. This 
is interesting in regard to the question whether tumor-spe- 
cific responses may be elicited with semi-allogeneic tumors 
as APCs.  Indeed, if differences at minor histocompatibility 
loci, as is the case in Our experiment, induce  a  T  cell re- 
sponse powerful enough to smother the response to tumor- 
specific antigens, it is likely that allogeneic responses would 
have the same outcome. 
There are reasons to suspect that public T  cell responses 
might be biologically and practically significant. Their re- 
current character indicates that they have been strongly se- 
lected. Furthermore, in the HEL transgenic model, the de- 
letion  of  public  cells  by  low  amounts  of  self  protein 
suggests that they may be of high avidity (3).  If this inter- 
pretation is proven  a  more  general rule,  it may influence 
future  immunotherapy  protocols  in  humans:  first,  public 
rearrangements,  if found  in  humans  sharing  HLA  alleles, 
might provide an easier and possibly predictable index for 
therapeutic  purposes.  Secondly,  it  might  be  desirable  to 
elicit  and/or  expand  (for  ex  vivo  immunotherapy)  high 
avidity T  cell (CTL) clones, and the identification of public 
specificities might be a means to access and characterize at 
least some  of them.  We are actively investigating whether 
the  above  concepts  may  serve  as  a  foundation  for  useful 
therapeutic principles, 
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